Fierce Healthcare

Lantheus Medical Imaging Announces FDA Accepts for Review DEFINITY® Supplemental New Drug Application for Use in Stress

N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Business Wire

New Lantheus Study Finds Significant Survival Benefit for Critically Ill Patients Undergoing Contrast-Enhanced Echocardiography

Transthoracic echocardiography, the most common type of echocardiogram, uses a transducer on a person’s chest to send high frequency ultrasound waves through the chest wall to the heart to create ...
Nasdaq

Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
Business Wire

Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY ® Room Temperature

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...
Reuters

US FDA: Concerns remain over heart imaging agents

WASHINGTON, June 20 (Reuters) - U.S. health regulators remain concerned about the safety of contrast agents used to enhance echocardiogram heart imaging tests, according to Food and Drug ...